Efficacy and Safety of Ipilimumab Plus Anti-PD-1/PD-L1 Antibodies Combination Therapy in Advanced Hepatocellular Carcinoma Patients Progressing After Multiple Lines of Treatment: A Retrospective Multicenter Study
Ipilimumab combination therapy in very late lines is a viable treatment option, although careful monitoring for adverse events is essential. Earlier application of this combination may potentially benefit patients more effectively.
Authors
- Boheng Zhang (ORCID: https://orcid.org/0000-0001-6040-2210)
- Yanfang Wu (ORCID: https://orcid.org/0000-0002-4225-3992)
- Zhenzhen Zhang (ORCID: https://orcid.org/0000-0002-5151-3602)
- Yijie Chen (ORCID: https://orcid.org/0000-0001-5502-7102)
- Jingfang Wu
- Su-Su Zheng
- Sheng Qian
Institutions
- Huaqiao University (CN)
- Shanghai Medical College of Fudan University (CN)
- Fudan University (CN)
- The 180th Hospital of PLA (CN)
- Zhongshan Hospital of Xiamen University (CN)
- Zhongshan Hospital (CN)
- Chinese People's Liberation Army (CN)
Publication Details
- Journal
- Journal of Hepatocellular Carcinoma
- Published
- 2025-03-01
- DOI
- https://doi.org/10.2147/jhc.s512302
- Citations
- 3
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 3.97